Insulin-delivery device maker Valeritas (NSDQ:VLRX) missed earnings and revenue expectations on Wall Street with its 1st quarter results. The Bridgewater, N.J.-based company pared its losses to -$11.9 million on sales of $4.6 million for the 3 months ended March 31, for bottom-line growth of 30% on sales loss of -8% compared with the same period last year. […]
Valeritas Inc.
Report: Insulin delivery devices improve adherence, lower costs
Valeritas (NSDQ:VLRX) touted data today from a publication detailing the benefits of diabetes medication delivery devices, such as the company’s V-Go insulin delivery system. The article was published in the journal Managed Care. The Bridgewater, N.J.-based company’s V-Go device is a wearable, basal-bolus insulin delivery system for patients with Type II diabetes. Patients can administer a continuous, […]
Diabetes: Medtronic furthers the quest for an artificial pancreas
Medtronic (NYSE:MDT) and Intarcia Therapeutics were in the spotlight at the American Diabetes Assn.’s annual scientific sessions conference in Boston last week, revealing new medical device developments in the fight against diabetes. Medtronic took center stage, announcing new developments for its artificial pancreas program, touting positive data from a user study of its MiniMed 640g and revealing plans to collaborate […]
